Cargando…

Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus: A Cohort Study

In this work we evaluate the prevalence of the antiphospholipid syndrome (APS) and its impact on survival in Chinese patients with systemic lupus erythematosus (SLE). We studied a prospective cohort of southern Chinese patients who fulfilled ≥4 American College of Rheumatology criteria for SLE. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Mok, Chi Chiu, Chan, Pak To, Ho, Ling Yin, Yu, Ka Lung, To, Chi Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553973/
https://www.ncbi.nlm.nih.gov/pubmed/23793109
http://dx.doi.org/10.1097/MD.0b013e31829cae47
_version_ 1782387984749821952
author Mok, Chi Chiu
Chan, Pak To
Ho, Ling Yin
Yu, Ka Lung
To, Chi Hung
author_facet Mok, Chi Chiu
Chan, Pak To
Ho, Ling Yin
Yu, Ka Lung
To, Chi Hung
author_sort Mok, Chi Chiu
collection PubMed
description In this work we evaluate the prevalence of the antiphospholipid syndrome (APS) and its impact on survival in Chinese patients with systemic lupus erythematosus (SLE). We studied a prospective cohort of southern Chinese patients who fulfilled ≥4 American College of Rheumatology criteria for SLE. The cumulative rate of survival over time was calculated by the Kaplan-Meier method. APS was defined by the 2006 updated consensus criteria. We evaluated the prevalence and manifestations of APS, and compared the survival of patients with and without APS. We followed 679 patients with SLE (92% women; age of onset, 32.5 ± 14 yr) for 9.7 ± 7.3 years. Sixty-eight (10%) patients died and 33 (4.9%) patients were lost to follow-up. Forty-four (6.5%) patients met the criteria for APS, manifested by the following: ischemic stroke (55%), deep venous thrombosis (32%), obstetric morbidity (14%), cardiovascular events (9%), and peripheral vascular disease (9%). Nine (9/44 [20%]) APS patients died, which was more frequent than the non-APS patients (59/635 [9%]; p = 0.02). The cumulative mortality of patients with APS was 4.6% at 5 years, 7.8% at 10 years, and 22.2% at 15 years, which was not significantly higher than that of non-APS patients (5.4% at 5 years, 9.2% at 10 years, and 11.3% at 15 years; p = 0.14). However, if we considered only patients with APS caused by arterial thrombosis, the presence of APS was significantly associated with mortality (hazard ratio, 2.29; 95% confidence interval, 1.13–4.64; p = 0.02). We conclude that the presence of APS increases the mortality risk of Chinese patients with SLE, which is mainly contributed by arterial thrombotic events. Clinical significance: 1) APS is infrequent in southern Chinese patients with SLE compared to white patients. 2) Arterial thrombosis is a more common manifestation of APS than venous thrombosis in Chinese SLE patients. 3) APS related to arterial thrombosis is associated with increased mortality in Chinese patients with SLE.
format Online
Article
Text
id pubmed-4553973
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-45539732015-10-27 Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus: A Cohort Study Mok, Chi Chiu Chan, Pak To Ho, Ling Yin Yu, Ka Lung To, Chi Hung Medicine (Baltimore) Original Study In this work we evaluate the prevalence of the antiphospholipid syndrome (APS) and its impact on survival in Chinese patients with systemic lupus erythematosus (SLE). We studied a prospective cohort of southern Chinese patients who fulfilled ≥4 American College of Rheumatology criteria for SLE. The cumulative rate of survival over time was calculated by the Kaplan-Meier method. APS was defined by the 2006 updated consensus criteria. We evaluated the prevalence and manifestations of APS, and compared the survival of patients with and without APS. We followed 679 patients with SLE (92% women; age of onset, 32.5 ± 14 yr) for 9.7 ± 7.3 years. Sixty-eight (10%) patients died and 33 (4.9%) patients were lost to follow-up. Forty-four (6.5%) patients met the criteria for APS, manifested by the following: ischemic stroke (55%), deep venous thrombosis (32%), obstetric morbidity (14%), cardiovascular events (9%), and peripheral vascular disease (9%). Nine (9/44 [20%]) APS patients died, which was more frequent than the non-APS patients (59/635 [9%]; p = 0.02). The cumulative mortality of patients with APS was 4.6% at 5 years, 7.8% at 10 years, and 22.2% at 15 years, which was not significantly higher than that of non-APS patients (5.4% at 5 years, 9.2% at 10 years, and 11.3% at 15 years; p = 0.14). However, if we considered only patients with APS caused by arterial thrombosis, the presence of APS was significantly associated with mortality (hazard ratio, 2.29; 95% confidence interval, 1.13–4.64; p = 0.02). We conclude that the presence of APS increases the mortality risk of Chinese patients with SLE, which is mainly contributed by arterial thrombotic events. Clinical significance: 1) APS is infrequent in southern Chinese patients with SLE compared to white patients. 2) Arterial thrombosis is a more common manifestation of APS than venous thrombosis in Chinese SLE patients. 3) APS related to arterial thrombosis is associated with increased mortality in Chinese patients with SLE. Wolters Kluwer Health 2013-07 2013-07-15 /pmc/articles/PMC4553973/ /pubmed/23793109 http://dx.doi.org/10.1097/MD.0b013e31829cae47 Text en Copyright © 2013 by Lippincott Williams & Wilkins
spellingShingle Original Study
Mok, Chi Chiu
Chan, Pak To
Ho, Ling Yin
Yu, Ka Lung
To, Chi Hung
Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus: A Cohort Study
title Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus: A Cohort Study
title_full Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus: A Cohort Study
title_fullStr Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus: A Cohort Study
title_full_unstemmed Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus: A Cohort Study
title_short Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus: A Cohort Study
title_sort prevalence of the antiphospholipid syndrome and its effect on survival in 679 chinese patients with systemic lupus erythematosus: a cohort study
topic Original Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4553973/
https://www.ncbi.nlm.nih.gov/pubmed/23793109
http://dx.doi.org/10.1097/MD.0b013e31829cae47
work_keys_str_mv AT mokchichiu prevalenceoftheantiphospholipidsyndromeanditseffectonsurvivalin679chinesepatientswithsystemiclupuserythematosusacohortstudy
AT chanpakto prevalenceoftheantiphospholipidsyndromeanditseffectonsurvivalin679chinesepatientswithsystemiclupuserythematosusacohortstudy
AT holingyin prevalenceoftheantiphospholipidsyndromeanditseffectonsurvivalin679chinesepatientswithsystemiclupuserythematosusacohortstudy
AT yukalung prevalenceoftheantiphospholipidsyndromeanditseffectonsurvivalin679chinesepatientswithsystemiclupuserythematosusacohortstudy
AT tochihung prevalenceoftheantiphospholipidsyndromeanditseffectonsurvivalin679chinesepatientswithsystemiclupuserythematosusacohortstudy